Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.682 EUR 1.79% Market Closed
Market Cap: 28.3m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/EBIT
Enterprise Value to EBIT

-2.8
Current
-0.8
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-2.8
=
Enterprise Value
22.2m EUR
/
EBIT
-7.8m EUR
All Countries
Close
Market Cap EV/EBIT
BE
Celyad Oncology SA
XBRU:CYAD
28.3m EUR -2.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 620.3
US
Abbvie Inc
NYSE:ABBV
320.5B USD 24.1
US
Amgen Inc
NASDAQ:AMGN
140.8B USD 30.3
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD 22.8
US
Epizyme Inc
F:EPE
94.1B EUR -495
AU
CSL Ltd
ASX:CSL
137B AUD 24.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 17.2
US
Seagen Inc
F:SGT
39.3B EUR -52.4
NL
argenx SE
XBRU:ARGX
36.5B EUR -102.9
EBIT Growth EV/EBIT to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBIT: 21.6
Negative Multiple: -2.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 620.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.3
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495 N/A N/A
AU
CSL Ltd
ASX:CSL
24.9
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A